By illustrating the unique diagnostic and therapeutic hurdles posed by delayed hypophysitis in anti-PD-1 therapy, this case contributes to the growing evidence on rare irAEs, reinforcing the importance of tailored surveillance strategies in oncology practice. Here, PDCD1 is linked to hypophysitis.